The Russian Direct Investment Fund (RDIF) announces the registration of the Russian Sputnik V vaccine against coronavirus by The National Administration of Drugs, Foods and Medical Devices of Argentina (ANMAT).

Argentina is the first country in Latin America to officially register Sputnik V. The vaccine was registered under the emergency use authorisation procedure and was approved by the regulator, ANMAT, based on the results of Phase III clinical trials in Russia, without additional trials in Argentina.

On December 10, RDIF and the Government of Argentina signed a contract for the supply of 10 million doses of Sputnik V vaccine to the country. ANMAT representatives inspected a number of vaccine production sites that will supply Sputnik V to Argentina.

Supplies of the vaccine to Argentina will be facilitated by international partners of RDIF in India, China, South Korea and other countries.

Kirill Dmitriev, CEO of the Russian Direct Investment Fund, commented, “Registration of the Sputnik V vaccine in Argentina without additional clinical trials in the country is a testament to Russian regulatory standards and the quality of clinical trials. We are ready to develop cooperation on the vaccine with other Latin American countries and we hope that they will take ANMAT’s decision into account.